PRINCETON, N.J., September 18, 2024--New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis Bristol Myers Squibb (BMY ...
PRINCETON, N.J., September 15, 2024--Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit... PRINCETON, N.J ...
Oral Solid Dosage Pharmaceutical Formulation Market is projected to achieve US$ 8,95,636.0 million by 2034 at a CAGR of 3.7%.